DK0804070T3 - Fremgangsmåde til isolering af proteiner fra mælk - Google Patents

Fremgangsmåde til isolering af proteiner fra mælk

Info

Publication number
DK0804070T3
DK0804070T3 DK94910120T DK94910120T DK0804070T3 DK 0804070 T3 DK0804070 T3 DK 0804070T3 DK 94910120 T DK94910120 T DK 94910120T DK 94910120 T DK94910120 T DK 94910120T DK 0804070 T3 DK0804070 T3 DK 0804070T3
Authority
DK
Denmark
Prior art keywords
milk
interest
isolating proteins
solubility
component
Prior art date
Application number
DK94910120T
Other languages
English (en)
Inventor
Julie S Denman
Edward S Cole
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DK0804070T3 publication Critical patent/DK0804070T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B11/00—Preservation of milk or dairy products
    • A23B11/10—Preservation of milk or milk preparations
    • A23B11/18—Preservation of milk or milk preparations by addition of preservatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/102—Caprine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/832—Milk; colostrum

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Tea And Coffee (AREA)
DK94910120T 1993-03-09 1994-02-17 Fremgangsmåde til isolering af proteiner fra mælk DK0804070T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2839593A 1993-03-09 1993-03-09
PCT/US1994/001672 WO1994019935A1 (en) 1993-03-09 1994-02-17 Isolation of components of interest from milk

Publications (1)

Publication Number Publication Date
DK0804070T3 true DK0804070T3 (da) 2000-08-07

Family

ID=21843236

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94910120T DK0804070T3 (da) 1993-03-09 1994-02-17 Fremgangsmåde til isolering af proteiner fra mælk

Country Status (11)

Country Link
US (1) US5756687A (da)
EP (1) EP0804070B1 (da)
JP (1) JP3801196B2 (da)
AT (1) ATE193301T1 (da)
AU (1) AU693436B2 (da)
DE (1) DE69424687T2 (da)
DK (1) DK0804070T3 (da)
ES (1) ES2146648T3 (da)
GR (1) GR3033500T3 (da)
PT (1) PT804070E (da)
WO (1) WO1994019935A1 (da)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268487B1 (en) * 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6011197A (en) 1997-03-06 2000-01-04 Infigen, Inc. Method of cloning bovines using reprogrammed non-embryonic bovine cells
EP0933029A1 (en) * 1998-02-03 1999-08-04 Xyrofin Oy Skimmed milk powder substitute
EP0947464A1 (en) * 1998-04-01 1999-10-06 Single Buoy Moorings Inc. Fluid transfer boom with coaxial fluid ducts
US20030005468A1 (en) * 1998-06-19 2003-01-02 Meade Harry M. Methods and vectors for improving nucleic acid expression
AU765315B2 (en) * 1998-11-19 2003-09-18 Pharming Intellectual Property Bv Stabilisation of milk from transgenic animals
US7030289B2 (en) 1998-11-19 2006-04-18 Ppl Therapeutics (Scotland) Ltd Stabilization of milk from transgenic animals
US6258998B1 (en) 1998-11-24 2001-07-10 Infigen, Inc. Method of cloning porcine animals
US6700037B2 (en) 1998-11-24 2004-03-02 Infigen, Inc. Method of cloning porcine animals
DK2112166T3 (da) 1998-12-23 2019-02-04 Pfizer Humane monoklonale antistoffer til CTLA-4
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
ES2299425T3 (es) * 1999-05-13 2008-06-01 Gtc Biotherapeutics, Inc. Antitrombina iii producida geneticamente y formas mutantes de la misma.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20040226052A1 (en) * 2000-10-13 2004-11-11 Meade Harry M. Methods of producing a target molecule in a transgenic animal and purification of the target molecule
EP2796468A2 (en) 2001-01-05 2014-10-29 Pfizer Inc Antibodies to insulin-like growth factor I receptor
WO2002072024A2 (en) * 2001-03-12 2002-09-19 Progenetics Llc Transgenic proteins from multi-gene systems, methods, compositions, uses and the like relating thereto
AU2002307554A1 (en) * 2001-04-23 2002-11-05 Abgenix, Inc. Anti-alpha3(iv)nc1 monoclonal antibodies and animal model for human anti-glomerular basement membrane autoantibody disease
EP1463522A4 (en) * 2001-05-16 2005-04-13 Einstein Coll Med HUMAN ANTIPNEUMOKOKKEN ANTIBODIES OF NON-THUMBAN ANIMALS
WO2002101021A2 (en) * 2001-06-13 2002-12-19 Taurus Hsa Llc Purification of human serum albumin
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US6578724B1 (en) * 2001-12-29 2003-06-17 United States Can Company Connector for use in packaging aerosol containers
IL164287A0 (en) * 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
KR100473703B1 (ko) * 2002-08-23 2005-03-10 한미약품 주식회사 형질전환 동물의 젖으로부터 재조합 펩타이드 또는단백질의 정제 방법
TWI268933B (en) * 2003-06-10 2006-12-21 Animal Technology Inst Taiwan Method for separating protein from animal milk
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
WO2005112968A2 (en) * 2004-04-30 2005-12-01 Gtc Biotherapeutics, Inc. Method of using recombinant human antithrombin for neurocognitive disorders
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
DK2287195T3 (da) 2004-07-01 2019-08-19 Innate Pharma Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
WO2006008639A1 (en) 2004-07-16 2006-01-26 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
AU2005291486A1 (en) * 2004-10-01 2006-04-13 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel antibodies directed to the mammalian EAG1 ion channel protein
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
WO2006096461A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
EP2384767B1 (en) 2005-03-24 2016-03-09 Millennium Pharmaceuticals, Inc. Antibodies that bind OV064 and methods of use therefor
BRPI0610248A2 (pt) 2005-04-25 2010-06-08 Pfizer anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos
KR101203328B1 (ko) 2005-04-26 2012-11-20 화이자 인코포레이티드 Ｐ-카드헤린 항체
US8642330B2 (en) * 2005-08-08 2014-02-04 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
HN2006031275A (es) 2005-09-07 2010-10-29 Amgen Fremont Inc Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
WO2007068255A1 (en) 2005-12-15 2007-06-21 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
CN101578297A (zh) * 2006-04-07 2009-11-11 美国政府健康及人类服务部 治疗肿瘤疾病的抗体组合物和方法
WO2008019290A2 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
EP2049661A4 (en) * 2006-08-04 2012-07-04 Pharmathene Inc RECOMBINANT BUTYRYLCHOLINESTERASE WITH LONG HALF-LIFE
CL2007002615A1 (es) * 2006-09-08 2008-04-18 Wyeth Corp Metodos para aislar o purificar un producto que comprende poner el producto enlazado en contacto con al menos una solucion de lavado que comprende arginina y luego eluir el producto; y dicho producto.
NZ576122A (en) 2006-09-26 2012-09-28 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
US8020576B2 (en) * 2006-10-26 2011-09-20 Delaware Capital Formation, Inc. Emergency shutoff valve for use in a fuel dispensing system
WO2008052796A1 (en) 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
EP2139924B1 (en) 2007-03-29 2016-07-06 Genmab A/S Bispecific antibodies and methods for production thereof
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
CN101939336B (zh) 2007-11-12 2014-05-14 U3制药有限公司 Axl抗体
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
KR101588736B1 (ko) 2008-01-10 2016-01-26 리서치 디벨롭먼트 파운데이션 얼리키아 샤피엔시스에 대한 백신 및 진단제
NZ590033A (en) 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2270053A1 (en) 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
CA2774032C (en) 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
CA2784861A1 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
EP2384766A1 (en) 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
EP3613774A1 (en) 2010-06-09 2020-02-26 Genmab A/S Antibodies against human cd38
AU2011267106B2 (en) 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
SG191716A1 (en) 2010-11-19 2013-08-30 Toshio Imai Neutralizing anti-ccl20 antibodies
WO2012090067A1 (en) 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
KR20140029446A (ko) 2011-04-15 2014-03-10 컴퓨젠 엘티디. 면역 관련 장애 및 암의 치료를 위한 폴리펩티드 및 폴리뉴클레오티드, 및 이들의 용도
US20140242182A1 (en) * 2011-07-07 2014-08-28 rEVO Biologics, Inc Formulations that stabilize proteins
EP2744517B1 (en) 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
ES2553597T3 (es) 2011-10-11 2015-12-10 Université D'aix-Marseille Un anticuerpo monoclonal anti-Tat del VIH-1
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
EP3093294A1 (en) 2012-02-24 2016-11-16 Stemcentrx, Inc. Dll3 modulators and methods of use
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
HK1207321A1 (en) 2012-04-26 2016-01-29 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
WO2013169377A1 (en) 2012-05-10 2013-11-14 Massachusetts Institute Of Technology Agents for influenza neutralization
CN104487453B (zh) 2012-06-15 2018-09-28 辉瑞公司 经改良的抗gdf-8的拮抗剂抗体及其用途
KR102165384B1 (ko) 2012-08-07 2020-10-16 메사추세츠 인스티튜트 오브 테크놀로지 항-뎅기 바이러스 항체 및 이들의 용도
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
CN105308068A (zh) 2013-02-13 2016-02-03 法国化学与生物科技实验室 高度半乳糖基化的抗TNF-α抗体及其用途
WO2014144666A2 (en) 2013-03-15 2014-09-18 The University Of Chicago Methods and compositions related to t-cell activity
WO2014197723A2 (en) 2013-06-05 2014-12-11 Massachusetts Institute Of Technology Human adaptation of h7 ha
JP6566941B2 (ja) 2013-06-28 2019-08-28 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 多発性硬化症のための樹状細胞ａｓｇｐｒ標的化免疫治療薬
KR20160029840A (ko) 2013-07-05 2016-03-15 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 친화성 크로마토그래피 매트릭스
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
EP3094652B1 (en) 2014-01-13 2021-09-29 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
CA2938495A1 (en) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
KR102485788B1 (ko) 2014-08-27 2023-01-09 메모리얼 슬로안 케터링 캔서 센터 항체, 조성물 및 용도
CN107001471B (zh) 2014-09-16 2022-01-18 西福根有限公司 抗met抗体和组合物
AU2016232749B2 (en) 2015-03-18 2021-09-23 The Johns Hopkins University Novel monoclonal antibody inhibitors targeting potassium channel KCNK9
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017027691A1 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
EP3334453A4 (en) 2015-08-13 2019-02-06 New York University ANTIBODY-BASED SPECIFIC MOLECULES AND THEIR USES IN THE DIAGNOSIS AND TREATMENT OF TAUOPATHY, FOR TAU'S SPECIFIC ASP421 EPITOP
EP3383418B1 (en) 2015-12-04 2021-10-20 Board of Regents, The University of Texas System Slc45a2 peptides for immunotherapy
NZ748983A (en) 2016-07-12 2022-12-23 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018019538A1 (en) 2016-07-28 2018-02-01 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Anti- immunoglobulin g aptamers and uses thereof
US11168148B2 (en) 2016-09-07 2021-11-09 The Regents Of The University Of California Antibodies to oxidation-specific epitopes
US10889635B2 (en) 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
WO2018109213A1 (en) 2016-12-16 2018-06-21 Laboratoire Français Du Fractionnement Et Des Biotechnologies Aptamers directed against a kappa light chain-containing protein and uses thereof
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN118047864A (zh) 2016-12-23 2024-05-17 百时美施贵宝公司 用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计
JP7217710B2 (ja) 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体
US11773182B2 (en) 2017-01-05 2023-10-03 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (PSMA)
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
EP3444275A1 (en) 2017-08-16 2019-02-20 Exiris S.r.l. Monoclonal antibody anti-fgfr4
KR102823603B1 (ko) 2017-10-12 2025-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 t 세포 수용체
CA3099547A1 (en) 2018-05-07 2019-11-14 Reshma Abdulla RANGWALA Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
SG11202009986QA (en) 2018-05-07 2020-11-27 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
BR112022008557A2 (pt) 2019-11-04 2022-08-09 Seagen Inc Conjugados de anticorpo-fármaco anti-cd30 e seu uso para o tratamento de infecção por hiv
MX2022005222A (es) 2019-11-07 2022-06-08 Genmab As Metodos para tratar el cancer con una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y un conjugado de anticuerpo anti factor tisular-farmaco.
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
IL293450A (en) 2019-12-03 2022-07-01 Evotec Int Gmbh Interferon-associated antigen binding proteins and uses thereof
US20230028476A1 (en) 2019-12-03 2023-01-26 Evotec International Gmbh Interferon-associated antigen binding proteins for use in treating hepatitis b infection
US12559575B2 (en) 2020-04-27 2026-02-24 The Regents Of The University Of California Isoform-independent antibodies to lipoprotein(a)
EP3909601A1 (en) 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
JP2023533937A (ja) 2020-06-29 2023-08-07 ジェンマブ エー／エス 抗組織因子抗体－薬物コンジュゲートおよびがん治療におけるその使用
IT202000015754A1 (it) 2020-06-30 2021-12-30 Fond Toscana Life Sciences Antibodies to coronavirus
WO2022003530A1 (en) 2020-06-30 2022-01-06 Fondazione Toscana Life Sciences Neutralizing antibodies to sars coronavirus-2
CN117580859A (zh) 2020-11-17 2024-02-20 思进股份有限公司 用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
CN117999085A (zh) 2021-06-09 2024-05-07 埃沃特克国际有限责任公司 用于治疗或预防冠状病毒感染的干扰素相关的抗原结合蛋白
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023094980A1 (en) 2021-11-23 2023-06-01 Fondazione Toscana Life Sciences Antibodies to coronavirus
EP4518904A1 (en) 2022-05-06 2025-03-12 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
US20260070961A1 (en) 2022-08-12 2026-03-12 Takeda Vaccines, Inc. Anti-denv3 antibodies
WO2024097725A1 (en) 2022-11-02 2024-05-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
WO2024126293A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
WO2024126294A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
WO2024126289A1 (en) 2022-12-13 2024-06-20 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
IT202300000924U1 (it) 2023-01-23 2024-12-22 Philomena Dove Cucitura all-up leggins seamless
WO2024213635A1 (en) 2023-04-12 2024-10-17 Evotec International Gmbh Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
EP4713360A1 (en) 2023-05-19 2026-03-25 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
IT202300015579A1 (it) 2023-07-25 2025-01-25 Fond Toscana Life Sciences Anticorpi contro covid-19 e altri coronavirus umani
WO2025046393A1 (en) 2023-08-25 2025-03-06 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Reagents against human endogenous retroviruses to target cancer cells
IT202300026115A1 (it) 2023-12-06 2025-06-06 Fond Per L’Istituto Oncologico Di Ricerca Ior Una strategia basata su anticorpi che mira ad erg oncogenico attivato nel cancro alla prostata
EP4635983A1 (en) 2024-04-15 2025-10-22 Ymmunobio AG A novel antibody binding specifically to nptxr and use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432718C1 (de) * 1984-09-06 1986-05-22 Biotest Pharma GmbH, 6000 Frankfurt Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5165945A (en) * 1987-07-23 1992-11-24 Schreiber Foods, Inc. Cheese and process and system for making it
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator
JPH04365487A (ja) * 1990-04-11 1992-12-17 Consortium Elektrochem Ind Gmbh 組換ｄｎａ−構造体、組換ベクター、トランスゲン動物の乳からの蛋白質の取得法、トランスゲン動物の製法及びトランスゲン動物の乳
US5175013A (en) * 1990-12-31 1992-12-29 The Pillsbury Company Frozen dessert compositions and products
FR2677652B1 (fr) * 1991-06-12 2005-05-27 Agronomique Inst Nat Rech Procede de preparation d'une proteine d'interet dans le lait d'un animal transgenique, produit obtenu et cellule eucaryote utilisee.
US5178894A (en) * 1991-09-26 1993-01-12 Silvia P. Rudel High non-fat milk content bread products having improved keeping qualities

Also Published As

Publication number Publication date
GR3033500T3 (en) 2000-09-29
JP3801196B2 (ja) 2006-07-26
JPH08510721A (ja) 1996-11-12
DE69424687T2 (de) 2000-09-07
PT804070E (pt) 2000-11-30
DE69424687D1 (de) 2000-06-29
WO1994019935A1 (en) 1994-09-15
EP0804070B1 (en) 2000-05-24
AU693436B2 (en) 1998-07-02
US5756687A (en) 1998-05-26
ATE193301T1 (de) 2000-06-15
ES2146648T3 (es) 2000-08-16
EP0804070A1 (en) 1997-11-05
AU6268394A (en) 1994-09-26

Similar Documents

Publication Publication Date Title
DK0804070T3 (da) Fremgangsmåde til isolering af proteiner fra mælk
FI883708L (fi) Menetelmä emäksisten proteiinien eristämiseksi proteiiniseoksista, jotka sisältävät tällaisia emäksisiä proteiineja
DE122009000068I2 (de) Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
NO20001052L (no) 1C, 15N, 2H merkede proteiner for NMR-strukturbestemmelser og deres fremstilling
GR3032843T3 (en) Methods and compositions for detecting binding of ligand pair using non-fluorescent label
EP1564550A3 (en) Method for analysis of proteins by solution isoelectric focusing
DK162233C (da) Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii
DK0408029T3 (da) Fremgangsmåde til fraktionering af plasmaprotein
ATE258598T1 (de) Verfahren zur proteinrückfaltung durch verwendung zwitterionischer wirkstoffe von niedrigem molekulargewicht
DK1123367T3 (da) Fremgangsmåde til separation af lipider og proteiner fra biologisk materiale
DE3865963D1 (de) Elektrophoretisches gel hoher aufloesung sowie methode zur abscheidung von serumproteinen.
DK0894091T3 (da) Fremgangsmåde til oprensning af et protein fra en proteinholdig opløsning
DK1054897T3 (da) Fremgangsmåde til oprensning af PrPres ud fra en biologisk pröve og anvendelser deraf
DK260186A (da) Fremgangsmaade til fjernelse af det n-terminale metionin fra metionylproteiner
DK1036166T3 (da) Fremgangsmåde til ekstraktion af udklækningsvæske fra atlantisk laks og anvendelse af denne væske
DK159441C (da) 11-substituerede 5,11-dihydro-6h-dibenz(b,e)azepin-6-on-derivater, laegemidler indeholdende disse forbindelser og analogifremgangsmaade til forbindelsernes fremstilling
GR3025929T3 (en) Ein isolation and purification of lung surfactant prot
DE58908969D1 (de) Verfahren zur Herstellung von 2-Chlor-5-chlormethylpyridin.
DE3585562D1 (de) Verfahren zur optischen untersuchungsanalyse von integrierten schaltungen.
CA2157118A1 (en) Isolation of components of interest from milk
DK0401657T3 (da) Fremgangsmåde til C-terminal modificering af proteiner
DK0796047T3 (da) Fremgangsmåde til isolering af valleproteiner
DK0454739T3 (da) Fremgangsmåde til isolering af oprenset EPI protein fra en opløsning, især en fermenteringsopløsning
DK0415557T3 (da) Separation af antimetalchelat-antistoffer
DK146591D0 (da) Fremgangsmaade og mellemprodukt til fremstilling af azetidinsulfonsyrederivater